Videos

VOWST Reels:
Healthcare professional videos

Guidance and experience from real VOWST prescribers

DR. PAUL FEUERSTADT

Watch Dr. Paul Feuerstadt speak about the threat of recurrent C. diff and how VOWST can help—an expert’s approach to a difficult-to-manage condition.

AMY STEWART, NURSE PRACTITIONER

Watch Amy Stewart, NP, outline her approach to prescribing VOWST, and why you don’t have to be a specialist to prescribe VOWST for the treatment of recurrent C. diff.

VOWST Reels:
Healthcare professional videos

Guidance and experience from real VOWST prescribers

DR. PAUL FEUERSTADT

Watch Dr. Paul Feuerstadt speak about the threat of recurrent C. diff and how VOWST can help—an expert’s approach to a difficult-to-manage condition.

AMY STEWART, NURSE PRACTITIONER

Watch Amy Stewart, NP, outline her approach to prescribing VOWST, and why you don’t have to be a specialist to prescribe VOWST for the treatment of recurrent C. diff.

Gut Busters
video series

Dispelling 5 common myths about VOWST among patients

DONOR MYTH

MANUFACTURING MYTH

LAXATIVE MYTH

PROBIOTIC MYTH

FMT MYTH

Gut Busters
video series

Dispelling 5 common myths about VOWST among patients

DONOR MYTH

MANUFACTURING MYTH

LAXATIVE MYTH

PROBIOTIC MYTH

FMT MYTH

ACCESS AND
REIMBURSEMENT RESOURCES

Explore available financial and
educational materials

SEE RESOURCES

REQUEST A REP

Contact a VOWST representative to
receive updates

CONTACT A VOWST REP

ABX, antibiotics.

ECOSPOR III
Multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in adults (≥18 years) with recurrent C. diff ^1-3
Primary Endpoint Recurrence at 8 weeks* Secondary Endpoints Adverse events within 24 weeks Recurrence at 4, 12, 24 weeks*
Recurrence confirmed with C. diff toxin test and ≥3 unformed bowel movements per day over 2 days*
10–21 days of vancomycin (125 mg QID) or fidaxomicin (200 mg BID)

ECOSPOR IV
Multicenter, open-label, single-arm trial in adults (≥18 years) with recurrent C. diff ⁵
Primary Endpoint Adverse events within 24 weeks Secondary Endpoints Recurrence at 4, 8, 12, 24 weeks
Recurrence confirmed with C. diff toxin test or PCR and ≥3 unformed bowel movements per day over 2 days^*
10–42 days of vancomycin or 10–25 days of fidaxomicin

ACCESS AND REIMBURSEMENT RESOURCES

REQUEST A REP

ACCESS AND
REIMBURSEMENT RESOURCES